Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease.

Contin M, Martinelli P, Mochi M, Albani F, Riva R, Scaglione C, Dondi M, Fanti S, Pettinato C, Baruzzi A.

Clin Neuropharmacol. 2004 May-Jun;27(3):111-5.

PMID:
15190232
2.
3.
4.

Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.

Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.

J Nucl Med. 1998 Jul;39(7):1143-8.

5.

Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.

Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB.

Ann Neurol. 1998 Jun;43(6):792-800.

PMID:
9629849
6.

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA.

J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133-40.

7.

Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.

Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, Janssen AG, Stoof JC, van Royen EA.

J Nucl Med. 1998 Nov;39(11):1879-84.

8.
9.

The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.

Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, Turk MF, Burnett OL.

Mov Disord. 1999 Nov;14(6):940-6.

PMID:
10584667
10.

Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.

J Nucl Med. 1998 Sep;39(9):1500-8.

12.

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, Seibyl JP.

Mov Disord. 1999 May;14(3):436-42.

PMID:
10348466
13.

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, Aarsland D, McKeith IG.

Arch Neurol. 2004 Jun;61(6):919-25.

PMID:
15210531
14.

Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.

Pöpperl G, Tatsch K, Ruzicka E, Storch A, Gasser T, Schwarz J.

J Neural Transm (Vienna). 2004 Aug;111(8):1041-52. Epub 2004 May 12.

PMID:
15254792
15.

Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.

Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, van Royen EA.

Eur J Nucl Med. 1997 Jan;24(1):68-71.

PMID:
9044880
17.

Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT.

Varrone A, Sansone V, Pellecchia MT, Amboni M, Salvatore E, De Michele G, Filla A, Barone P, PappatĂ  S, Salvatore M.

Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1343-9. doi: 10.1007/s00259-008-0729-x. Epub 2008 Feb 19.

PMID:
18283454
18.

123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.

Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, Schillaci O.

Nucl Med Commun. 2005 May;26(5):421-6.

PMID:
15838424
19.

One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.

Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA.

J Nucl Med. 1999 May;40(5):753-61.

20.

Do dopamine agonists or levodopa modify Parkinson's disease progression?

Marek K, Jennings D, Seibyl J.

Eur J Neurol. 2002 Nov;9 Suppl 3:15-22. Review.

PMID:
12464117

Supplemental Content

Support Center